Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Hepatocellular 2 Thyroid Nodule 1 Prostatic Neoplasms 1 Multiple Pulmonary Nodules 1 Hyperaldosteronism 1 Carcinoma, Renal Cell 1 Bone Cancer Metastatic 1 Barrett Esophagus 1 Adenocarcinoma Of Esophagus 1 Adenocarcinoma 1 ACTH Syndrome, Ectopic 1

Interventions

Oxaliplatin 9 Capecitabine 9 Fluorouracil 7 pembrolizumab 6 Paclitaxel 6 Leucovorin 6 Cisplatin 5 zolbetuximab 4 trastuzumab deruxtecan 3 enzalutamide 3 durvalumab 3 cemiplimab 3 Trastuzumab 3 Gemcitabine 3 Docetaxel 3 fludarabine 2 darolutamide 2 Taxes 2 Ramucirumab 2 Radiotherapy, Image-Guided 2 Radiosurgery 2 Pemetrexed 2 Nivolumab 2 Irinotecan 2 Cyclophosphamide 2 Carboplatin 2 Albumin-Bound Paclitaxel 2 130-nm albumin-bound paclitaxel 2 vistusertib 1 tucatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Adenocarcinoma × Radiofrequency Ablation × 90 days × Clear all

NCT07237399 2026-05-13

TA-P-OLIM

University Hospital, Ghent

Adenocarcinoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡